Avraham Pharmaceuticals Announces Commencement of a Phase 2 Study of Ladostigil for the Treatment of MCI

News   May 18, 2012

 
Avraham Pharmaceuticals Announces Commencement of a Phase 2 Study of Ladostigil for the Treatment of MCI
 
 
 

RELATED ARTICLES

Symmetry-breaking Method Opens Way for Bioactive Compounds

News

EPFL chemists have developed a new catalytic method for symmetry breaking. Published in Angewandte Chemie, the method can help synthesize important building blocks for bioactive compounds such as anticancer drugs.

READ MORE

Investigational Drug for Melanoma Shows Promise in Early-Stage Study

News

An investigational compound designed to block a hyperactive cell growth signal in advanced melanoma and other cancers has shown some promise in an early-stage clinical trial researchers have reported.

READ MORE

Scientists Report The Development of a Potent New Medicine to Fight Addiction

News

Scientists report the development of a potent new medicine to fight addiction.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE